anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a fructo-oligosaccharide tablet excipient which includes, by weight, 88% to 96% of fructo-oligosaccharide, 1% to 5% of an octenyl succinic anhydride modified starch, 1% to 5% of silicon dioxide and 1% to 5% of kaolin. The fructo-oligosaccharide tablet excipient is good in liquidity, molding, and demoulding, and can be used for preparing medicine tablets with medicine and water through direct compression. The invention further discloses a medicine tablet which includes, by weight, 75% to 85% of an active pharmaceutical ingredient, 5% to 15% of the fructo-oligosaccharide tablet excipient and 5% to 15% of water. The fructo-oligosaccharide tablet excipient and the active pharmaceutical ingredient have no incompatibility and reaction, have good dissolubility and liquidity, and are suitable for direct compression of various medicines. The invention further discloses a preparation method of the medicine tablet. The preparation method is simple, and easy to implement, operate and control.
PURPOSE:To obtain the titled composition, by using a composition containing ethanol as an active ingredient and an extract of plants selected from Polygala senega L., Eugenia caryophyllata Thunb., Forsythia suspensa Vahl., etc., together, capable of moderating the irritation of the ethanol and sufficiently exhibiting antimicrobial effect and having excellent feeling of use. CONSTITUTION:A composition for the oral cavity obtained by blending a composition for the oral cavity containing ethanol in an amount of >=5wt%, particularly 5-30wt% based on the total composition with one or two or more extracts of plants selected from Polygala senega L., Eugenia caryophyllata Thunb., Forsythia suspensa Vahl., Lonicera japonica, thunb., and Polygala tenuifolia Willd. The amount of the extracts of the plants blended with the composition is 0.0001-2%, particularly preferably 0.001-1% based on the total composition. As for the plants to be a raw material for the extracts, roots of the Polygala senega L. of the family Polygalaceae are effectively used particularly as the Polygala senega L. and flowered buds, barks, etc., of the Eugenia caryophyllata Thunb. of the family Myrtaceae are effectively used as the Eugenia caryophyllata Thunb. Fruits, pericarps, etc., of the genus Forsythia of the family Oleaceae are effectively used as the Forsythia suspensa Vahl., etc.
Corticosteroids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. Since corticosteroids may inhibit the body's defense mechanism against infection, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant in a particular case.

Corticosteroids are capable of producing a rise in intraocular pressure. In clinical studies of documented steroid-responders, fluorometholone demonstrated a significantly longer average time to produce a rise in intraocular pressure than dexamethasone phosphate; however, in a small percentage of individuals, a significant rise in intraocular pressure occurred within one week. The ultimate magnitude of the rise was equivalent for both drugs.

The anti-infective component in FML-S® ophthalmic suspension is included to provide action against specific organisms susceptible to it. Sulfacetamide sodium is active in vitro against susceptible strains of the following microorganisms: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. Some strains of these bacteria may be resistant to sulfacetamide or resistant strains may emerge in vivo.

When a decision to administer both a corticosteroid and an antimicrobial is made, the administration of such drugs in combination has the advantage of greater patient compliance and convenience, with the added assurance that the appropriate dosage of both drugs is administered. When both types of drugs are in the same formulation, compatibility of ingredients is assured and the correct volume of drug is delivered and retained.

The relative potency of corticosteroid formulations depends on the molecular structure, concentration, and release from the vehicle.
Articular cartilage injuries in the knee continue to grow in number as detection and treatment options have advanced. Treatment options, including microfracture, autologous chondrocyte (cells that make cartilage) implantation, osteochondral grafting and meniscus transplantation can hopefully deter the progression of degeneration and have promise to function as disease modifying solutions. Osteochondral allograft transplantation (OCA) has emerged as a preferred method of treating large focal chondral defects as it structurally replaces the cartilage and often involved sub-chondral bone with native hyaline cartilage and bone. The results of OCA are successful with greater than 85% survival at 5-year follow-up. Failure can occur due to a lack of boney integration or low chondrocyte viability. Therefore, anything to enhance the graft augmentation process may be useful in preventing failure. The purpose of this prospective, randomized study is to determine the effect of bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells on improving graft incorporation and preventing failure. The effect of BMAC on the graft and intra-articular knee environment will be evaluated using 3 techniques: computed tomography (CT) imaging, synovial fluid cytokine analysis, and serum biomarker analysis. Information learned from this study can be used to biochemically compare treatment response and to assess emerging therapeutic options that may positively alter the biochemical environment in patients undergoing osteochondral allograft transplantation.
PURPOSE:To obtain the objective composition for oral cavity application exhibiting specific antibacterial action against Streptococcus mutans, free from influence upon other normally existing bacteria and effective in preventing the formation of dental plaque and dental caries by using tormentic acid or its salt as an active component. CONSTITUTION:The objective composition contains tormentic acid or its salt which is a pentacyclic acidic triterpene compound existing in nature e.g., in a plant of genus Comanthosphace, family Labiatae, etc. The compound of formula can be used as a composition for oral cavity application by mixing with a proper excipient, adjuvant, etc., and forming into a drug or by adding to conventional food. The preferable form of the composition is dentifrice, gargle, liquid ointment, troche, chewing gum, candy, drink, etc. The concentration of the compound of formula in the composition in use is preferably >=0.005(w/v)%. The composition is especially useful for the prevention of dental caries of infant.
BACKGROUND: Heavy menstrual bleeding affects up to one third of menstruating individuals and has a negative impact on quality of life. The diagnosis of heavy menstrual bleeding is based primarily on history taking, which is highly dependent on traditional disposable menstrual products such as pads and tampons. Only tampons undergo industry-regulated testing for absorption capacity. As use of alternative menstrual products is increasing, there is a need to understand how the capacity of these products compare to that of standard products.
METHODS: A variety of commercially available menstrual products (tampons, pads, menstrual cups and discs, and period underwear) were tested in the laboratory to determine their maximal capacity to absorb or fill using expired human packed red blood cells. The volume of blood necessary for saturation or filling of the product was recorded.
RESULTS: Of the 21 individual menstrual hygiene products tested, a menstrual disc (Ziggy, Jiangsu, China) held the most blood of any product (80 mL). The perineal ice-activated cold pack and period underwear held the least (<3 mL each). Of the product categories tested, on average, menstrual discs had the greatest capacity (61 mL) and period underwear held the least (2 mL). Tampons, pads (heavy/ultra), and menstrual cups held similar amounts of blood (approximately 20-50 mL).
CONCLUSION: This study found considerable variability in red blood cell volume capacity of menstrual products. This emphasises the importance of asking individuals about the type of menstrual products they use and how they use them. Further understanding of capacity of newer menstrual products can help clinicians better quantify menstrual blood loss, identify individuals who may benefit from additional evaluation, and monitor treatment.
The invention comprises compounds of the formula: <FORM:0950159/C2/1> (wherein S denotes alkyl, alkoxy, aralkoxy, hydroxy or alkylenedioxy substitution occupying not more than 3 positions and includes at least one alkoxy group, alkylenedioxy being regarded as 2 alkoxy groups in this context, and S1 denotes alkyl, alkoxy, aralkoxy, hydroxy, nitro, halogeno or alkylenedioxy substitution occupying not more than 3 positions, and in which the broken lines denote bonds to optional groups) and acid-addition salts thereof; and their preparation by condensing a dihydroisoquinolinium salt of the formula: <FORM:0950159/C2/2> (wherein A- is an anion) with the appropriate ketone in the presence of a basic agent. Examples are given and the separation of products into optical isomers is also referred to.  Dihydroisoquinolinium salts of the second general formula above are obtained by quaternization of the corresponding 3,4-dihydroisoquinoline.  6 - Benzyloxy -7- methoxy-3, 4-dihydroisoquinoline is prepared by converting (3-benzyloxy-4-methoxy-phenyl)-ethylamin to its formamide and cyclizing this, the oxalate of the product being also prepared. 2-Ethyl-4, 5-dimethoxyacetophenone is prepared from 1-ethyl-3, 4-dimethoxybenzene and acetyl chloride.  The tetrahydroisoquinoline derivatives of the invention, which are stated to possess analgesic and antitussive properties, may be made up into pharmaceutical compositions with suitable carriers. These may take the form of dragees, tablets, capsules, suppositiories, solutions, suspensions or emulsions, and may contain preservatives, stabilizers, wetting or emulsifying agents, salts for varying osmotic pressure or buffers. Ampoules containing 1-[(p-chlorobenzoyl)-methyl] -2- methyl-6, 7-dimethoxy -1, 2, 3, 4-tetrahydroisoquinoline citrate and tablets containing the corresponding hydrochloride are described.
The value of oral anticoagulants such as coumarin derivatives as a therapy and in the prophylaxis of thrombosis is universally acknowledged. These medicinal products are used in the prevention of cerebral infarction, in patients with atrial fibrillation and in the secondary prevention of myocardial infarction. In case of elected surgery, the effect of coumarin derivatives can be reversed by a termination of the coumarin treatment and the administration of vitamin K orally, i.m. or i.v., which will restore the production of the vitamin K dependent coagulation factors. For patients due to undergo acute surgery, it will be unfavourable to await endogenous production of vitamin K dependent coagulation factor production.After CPB surgery, the patients need to be in a controlled coagulated state. Two products suitable to rapidly increase the concentration of vitamin K dependent coagulation factors, are fresh frozen plasma (FFP) and prothrombin complex concentrates (PCC). These products contain factor II, VII, IX and X and help to restore normal levels of the clotting fraction.Administration of these products prior to CPB surgery will decrease the INR to a level that is acceptable for surgery. In the Academic Hospital Leuven the standard procedure in cases of acute and elected CPB surgery is administration of VP-VI, a FFP-product made by OCTAPHARMA. In this study the standard treatment of 2x 400 ml VP-VI was compared with a treatment of PPSB Solvent Detergent® (PPSB-SD) according to the prescription regimen of CAF-DCF. PPSB-SD is a PCC product made by Sanquin Plasma Products (the Netherlands) for CAF-DCF (Belgium). The regimen as prescribed by CAF-DCF enables to calculate the quantity of PPSB-SD to administer on the basis of the patient's weight, the initial INR and the target INR. The expected outcome of the study was that in patients receiving PPSB-SD the target INR will be reached more frequently and more rapidly compared to patients receiving VP-VI.
Couples will be randomized to a comprehensive weight program directed at patients alone or involving their partners. In months 1-6, all patients will receive group-based weight loss program. In months 7-18, all patients will receive a telephone-based weight loss maintenance intervention. In the partner-assisted arm only, partners will participate in the intervention, learning and practicing communication skills and support strategies. In months 19-24, intervention will be withdrawn to examine sustainability of effects.

Due to COVID-19, option of doing screening and outcome assessment visits and attending the group classes (including exercise) remotely via a video conference may be available. COVID-19 survey will be administered every 3 month starting at screening/enrollment visit.
PURPOSE:To provide an antibacterial composition containing apolactoferrin and lysozyme as active components and useful for curing infectious diseases, suppressing the proliferation of harmful bacteria in intestines and promoting the prophylactic activity of living body. CONSTITUTION:The objective composition contains apolactoferrin and lysozyme as active components at a weight ratio of 5:95-95:5. Apolactoferrin can be separated from cow's colostrum, transitional milk, normal milk or late lactation milk and lysozyme can be separated from albumen. An apolactoferrin having iron saturation degree of <=20wt% can be used for the purpose. Apolactoferrin is a protein produced by removing iron from lactoferrin which is an iron-bonded protein and has iron-bonding and fixing property. Accordingly, iron component required by bacteria is bonded with apolactoferrin before the component is absorbed and taken by the bacteria to suppress the proliferation of the bacteria by the lack in iron.
Treatment of rotator cuff tears can be conservative or surgical. The aim of rehabilitation postoperative period, is to reduce pain, increase joint range of motion (ROM), and enable the patient to return to normal functional activities as soon as possible while preventing the repaired tissue from tearing again.

Motor control training based on motor control theory reorganizes the cerebral cortex. In people with shoulder pain, a scapulothoracic posture retraining program reduces shoulder pain and improves scapulothoracic movement and muscle activation patterns and shoulder function. Therefore, rehabilitation should include correct positioning of the scapulothoracic joint through active muscle activation (motor control training) and retraining. However, the evidence is still limited and the effect of motor control exercises is not yet fully understood. Over the last 15 years, telerehabilitation in the broader field of telehealth has been used to help patients in rural areas improve healthcare and access services to reduce cost and transportation issues. Studies on the upper extremity have also begun to increase in recent years. The aim of the study is to examine the effect of motor control exercises given through telerehabilitation on shoulder function and quality of life in patients undergoing rotator cuff surgery.
A method and system is described which facilitates the proper association of radiographic film with a patient information. The invention maintains information for each patient to be examined in the current day and generates a unique identifying ID code for each patient to be examined. Before examining a patient, the current patient's unique identifier is imaged on an unexposed radiographic film. After the patient is examined and the film is exposed, the film is developed and digitized. Patient information is retrieved and associated with the digitized medical images by analyzing the digital image data in order to determine the patient's unique identifier. In this manner, the invention ensures the proper association of patient information with exposed radiographic film. Once properly associated, the digital image data and the patient information can be communicated to a Picture Archiving and Communication System. The present invention also allows for interfacing with a hospital's Radiology Information System, thus eliminating the need for manual entry of patient information.
Participants with cIAI or cUTI will receive imipenem/cilastatin/relebactam (IMI/REL) via IV infusion, once every 6 hours, for a minimum of 5 days (with optional oral switch after 3 days) up to a maximum of 14 days. Participants with HABP/VABP will receive IMI/REL via IV infusion, once every 6 hours, for a minimum of 7 days up to a maximum of 14 days. All oral switch medications will be chosen from a list of acceptable approved agents and will be administered per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines.
A new treatment manipulating intention substrates for language production in "nonfluent" aphasia patients was developed. The intention component involves initiating word-finding trials with a complex left-hand movement. The study addresses (1) whether or not the intention manipulation (complex left-hand movement) makes a unique contribution to treatment outcome and (2) whether or not the intention manipulation helps to shift word production mechanisms from the left to the right frontal lobe. All study participants take part in functional magnetic resonance imaging (fMRI) scans of word-finding before and after treatment and at 3-month follow-up to measure changes in lateralization of frontal lobe activity during word finding. Only patients with a substantial degree of left frontal activity on the pre-treatment fMRI scan can participate. There are three specific aims: (1) to determine if repetitive initiation of word production with a complex left-hand movement leads to increased right-hemisphere lateralization of frontal activity and if these changes can be attributed to the intention component of treatment, (2) to determine whether activity in posterior perisylvian cortices that is entrained to right frontal activity shows a greater increase in right-hemisphere lateralization from pre- to post-treatment fMRI when the intention component is included in treatment, and (3) to determine whether onset of hemodynamic responses (HDRs) in right motor/premotor cortex becomes more closely associated with the temporal onset of participants' spoken responses across treatment when the intention component is included in treatment. If successful, the treatment can provide a new treatment vehicle for increasing language function in patients with "nonfluent" aphasia.
PURPOSE:To obtain an antibody useful for e.g. diagnosing or treating chronic arthrorheumatism because of being capable of easily, quickly and accurately assaying an antigen, i.e., a synthetic peptide having an amino acid sequence specific to a human phospholipase A2-activated protein. CONSTITUTION:Firstly, a peptide having an amino acid sequence of the formula and specific to a human phospholipase A2-activated protein (PLAP) is synthesized, and cysteine residue is introduced into the C-terminal of this peptide followed by binding the resultant peptide to e.g. maleimide-modified Tachypleus tridentatus hemocyanin (KLH) to prepare an antigen. Second, this antigen, together with an adjuvant, is administered to BALB/C mice, and after the final immunization, the splenocytes are taken and fused with myeloma cells, and the resultant hybridoma are cultured in a HAT selective medium to select the clone capable of producing the aimed antibody, and this clone is then cloned by limiting dilution analysis; the monoclonal hybridoma produced is then cultured, thus obtaining the aimed new anti-PLAP monoclonal antibody useful for e.g. PLAP-as saying reagents.
The intervention of this group consists in usual treatment in Primary Care provided by Endocrinology Services. 3 monthly face-to-face consultations and continuous online monitoring are provided to these families, oriented to promote healthy habits of nutrition and physical activity for 6 months. It works from an exclusively behavioural perspective. A token economy is used with the families as a system of contingency management based on the systematic reinforcement of target behaviour.
PURPOSE: A cosmetic composition for skin cell death prevention containing fermented red ginseng extracts is provided to increase the expression of SIRT3 which is well known for a longevity gene. CONSTITUTION: A cosmetic composition for skin cell death prevention contains fermented red ginseng extracts. The fermented red ginseng extract is obtained by inoculating Tricoderma reesei and aspergillus niger on the red ginseng extract and cultivating thereof after inoculating lactobacillus in the extract of red ginseng and fermenting thereof. The lactobacillus is Lactobacillus fermentum. 0.0001-10 wt% of the fermented red ginseng extract is included in the cosmetic composition. The cosmetic composition has formulations of lotion(tonic), nutritive lotion, moisturizing cream, massage cream or nutritious essence. A manufacturing method of the fermented red ginseng extracts comprises the following steps: obtaining the red ginseng extract by using the red ginseng extraction solvent; inoculating the lactobacillus fermentum in the extract of red ginseng and fermenting thereof are 30-37 deg. Celsius for 3-4 days; respectively inoculating aspergillus niger and Trichoderma reesei in the fermentation liquid and cultivating at 25-30 deg. Celsius for 3-4 days; and obtaining the red ginseng extract by aging, heat treating and filtering the culture fluid. [Reference numerals] (AA) Expression amount of SIRT mRNA(%); (BB) Resveratrol; (CC) Fermented red ginseng 10; (DD) Fermented red ginseng 50; (EE) Fermented red ginseng 100; (FF) Fermented red ginseng 10; (GG) Fermented red ginseng 50; (HH) Fermented red ginseng 100
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease, characterized by raised blood glucose levels and impaired lipid metabolism resulting from insulin resistance and relative insulin deficiency. In diabetes, the peculiar plasma lipoprotein phenotype, consisting in higher levels of apolipoprotein B-containing lipoproteins, hypertriglyceridemia, low levels of HDL cholesterol, elevated number of small, dense LDL, and increased non-HDL cholesterol, results from an increased synthesis and impaired clearance of triglyceride rich lipoproteins. This condition accelerates the development of the atherosclerotic cardiovascular disease (ASCVD), the most common cause of death in T2DM patients. Here, we review the alteration of structure, functions, and distribution of circulating lipoproteins and the pathophysiological mechanisms that induce these modifications in T2DM. The review analyzes the influence of diabetes-associated metabolic imbalances throughout the entire process of the atherosclerotic plaque formation, from lipoprotein synthesis to potential plaque destabilization. Addressing the different pathophysiological mechanisms, we suggest improved approaches for assessing the risk of adverse cardiovascular events and clinical strategies to reduce cardiovascular risk in T2DM and cardiometabolic diseases.